Latest Conference Articles

Multiple sclerosis is perceived differently by the patient and physician – after all, they’re in two different boats. However, this disconnect could make managing the disease a more complicated journey.

"It's great that we have more tools for HIV prevention, but we should also work on the conditions that put people at risk."

AIDS activists have not lost their zeal for protest. At a pharma-sponsored luncheon, a band of activists criticizing the price of antivirals brought things to a brief halt.

Despite the development in HIV/ADIS research, "We are not close to where we should be or where we'd like to be," shared Carlos Rodriguez Diaz, PhD, University of Puerto Rico.

WIth high rates of HIV infection among black and Latino men who have sex with men, a dozen cities in the US have started trial programs aimed at getting HIV negative MSM to embrace pre-exposure prophylaxis, both "holistic" and pharmaceutical.

Unlike conditions like multiple sclerosis where there is a considerable amount of knowledge and several available approved treatment options that is not the case for neuromyelitis optica. As a result more work is needed to educate patients about what their treatment will be like.

There are currently no medications approved for the treatment of neuromyelitis optica. However, there are clinical trials underway and more research being done to change that in the coming years.

Ending this epidemic isn't just about stopping HIV, it's about really giving value and respect to sexual health and sexual well being.

With multiple medications approved to treat multiple sclerosis there is more work being done to help a larger patient population through the course of disease treatment.

It has been a few years now since Tecfidera was approved by the US Food and Drug Administration. In that time there has bee continued research which has shown positive results for patients.

HIV isn't just an issue of health or public health; rather, HIV is a magnifying glass to a myriad of social justice and human rights challenges that will not go away even if we end HIV.

There has never been a randomized, controlled study that compared natalizumab and fingolimod for relapsing-remitting multiple sclerosis (RRMS) – until now at ECTRIMS 2016 in London, England.

Having been recently approved for patients with the relapsing form of multiple sclerosis more data is being done to show ways it can help manage symptoms while also being a safe option.

In a study led by Jérôme de Seze, MD, PhD, from the University Hospital of Strasbourg in France, researchers aimed to uncover more information on the medication, ocrelizumab, in patients with primary progressive multiple sclerosis (PPMS).

Recent findings have shown that vitamin D supplements improve multiple sclerosis (MS) relapse rates, however, a new study questions when those levels come into play.

“Although the etiology of multiple sclerosis (MS) remains elusive, it is clear that Epstein Barr Virus (EBV) and possibly other viruses have a role in the pathogenesis of MS,” researchers started a presentation at ECTRIMS 2016 in London, England.

Studies tend to yield better results than those found in a real-world setting. So to find “real” clinical outcomes with teriflunomide in patients with multiple sclerosis (MS), researchers conducted a phase 4 trial.

Delayed-release dimethyl fumarate (DMF) has yielded positive results in multiple sclerosis (MS) studies, however, the data has been limited to a particular population.

"The is no one living with HIV in this country who shouldn't have access to a treatment combination that works for them."

From showgirls to scientists, attendees at the 20th Annual US Conference on AIDS found much to celebrate and a lot left to be done in the quest to conquer HIV/AIDS.

According to Charles King, President and CEO of Housing Works, "It really doesn't matter what part of the world you're in. If you're having to struggle with issues around sexism, racism, homophobia, transphobia, homelessness, addiction, mental illness, they are all drivers of very bad health outcomes for people - whether you're talking about HIV, hepatitis C, or tuberculosis."

The treatment of multiple sclerosis has come a long way in recent years. However, there is a lot more to be done. There is optimism that over time treatment can be even more effective and help even more patients as new treatment methods are developed.

David Ho, MD, has been a pioneer in the development of AIDS antivirals, starting with his work on protease inhibitors 20 years ago. Kicking off the US Conference on AIDS today in Hollywood, FL, Ho said a new bi-monthly injection is looking like the next breakthrough in HIV/AIDS prevention.

Patients diagnosed with relapsing remitting multiple sclerosis have seen their treatment options increase dramatically in recent years. Now patients with the progressive forms are seeing the the start of momentum building in their favor.

Multiple sclerosis in itself has not shown to increase spontaneous abortions, stillbirth, cesarean delivery, premature birth, or birth defects – but what about the treatments?

Ravi Prasad, Phd, Stanford University, shared his work with the Stanford Comprehensive Interdisciplinary Pain Program to help improve patient quality of life.

A phase 3 study presented at PAINWeek 2016 in Las Vegas, Nevada, showed the benefits of using an electronic tracking system.

Whether it’s drugs or procedures, there are different strategies for managing chronic pain. However, when psychological symptoms come into play, treatment may need to take an alternative course.

In a perfect world, the pain data provided by diagnostic tests would match up with how a patient is actually feeling. However, the association is probably not as strong as doctors would like.

Researchers behind the potential new opioid, cebranopadol, presented efficacy and safety results at PAINWeek 2016 in Las Vegas, Nevada.